Based on findings in our studies, next step pharmaceutical and clinical studies are warranted to design OXT analogs that have optimal therapeutic effects via peripheral administration to treat obesity, diabetes and related metabolic diseases. Here, OXT is linked to obesity due to melanocortin 4 receptor deficiency.